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ABSTRACT
AMPK (AMP-activated protein kinase) is a heterotrimetric enzyme that is expressed in many
tissues, including the heart and vasculature, and plays a central role in the regulation of energy
homoeostasis. It is activated in response to stresses that lead to an increase in the cellular
AMP/ATP ratio caused either by inhibition of ATP production (i.e. anoxia or ischaemia) or by
accelerating ATP consumption (i.e. muscle contraction or fasting). In the heart, AMPK activity
increases during ischaemia and functions to sustain ATP, cardiac function and myocardial viability.
There is increasing evidence that AMPK is implicated in the pathophysiology of cardiovascular
and metabolic diseases. A principle mode of AMPK activation is phosphorylation by upstream
kinases [e.g. LKB1 and CaMK (Ca2+/calmodulin-dependent protein kinase], which leads to direct
effects on tissues and phosphorylation of various downstream kinases [e.g. eEF2 (eukaryotic
elongation factor 2) kinase and p70 S6 kinase]. These upstream and downstream kinases of
AMPK have fundamental roles in glucose metabolism, fatty acid oxidation, protein synthesis and
tumour suppression; consequently, they have been implicated in cardiac ischaemia, arrhythmias
and hypertrophy. Recent mechanistic studies have shown that AMPK has an important role in
the mechanism of action of MF (metformin), TDZs (thiazolinediones) and statins. Increased
understanding of the beneﬁcial effects of AMPK activation provides the rationale for targeting
AMPK in the development of new therapeutic strategies for cardiometabolic disease.
INTRODUCTION
The prevalence of cardiometabolic diseases is reaching
epidemic proportions in industrialized nations and in
developing countries [1–3]. Despite aggressive treatment
of the individual cardiometabolic risk factors, death
from cardiometabolic conditions remains unacceptably
high. Therefore there is an urgent need to identify new
strategies for treating and preventing cardiometabolic
diseases. In this respect, the AMPK (AMP-activated
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protein kinase) pathway has become the focus of a
great deal of attention as a novel therapeutic target in
cardiometabolicdiseasebecauseithasbeendemonstrated
to mediate, at least in part, the effects of a number of
physiological and pharmacological factors that exert
beneﬁcial effects on the vasculature and the heart.
AMPKhasseveralimportantmetaboliceffects,including
increasing muscle glucose uptake [4,5] and ameliorat-
ing insulin resistance [6]. It regulates cardiac muscle
glucose and lipid metabolism both directly and indirectly
in order to provide ATP in response to energy
depletion (speciﬁcally a rise in the AMP/ATP ratio).
AMPK activity can also be modulated by hormones and
adipocytokineswhichmayhaveprotectiveeffectsagainst
cardiovascular disease. AMPK has also been shown to
regulate transcription of genes involved in lipid and
glucose metabolism [7,8]. Dysregulation of this process
(for example in obesity) can lead to the development of
insulin resistance and dyslipidaemia, both of which are
major risks factors for CVD (cardiovascular disease).
Thus the identiﬁcation of a compound that speciﬁcally
andsafelyactivatestheAMPKpathwaymightcontribute
signiﬁcantly to the treatment, management and even
prevention of CVD. The aim of the present review is to
discuss the direct and indirect role of AMPK in normal
cardiac physiology and in cardiometabolic disease, and
therapeutic strategies in modulating APMK activity.
STRUCTURE AND REGULATION OF AMPK
Understanding of the role of AMPK in key physiological
pathways has increased several fold in recent years. Its
discoverycanbetracedbacktotwoindependentﬁndings
reported in 1973 that observed that crude preparations
of ACC (acetyl-CoA carboxylase) [9] and HMG-CoA
(3-hydroxy-3-methylglutaryl-CoA) reductase [9a] be-
came inactivated when incubated with ATP. Both groups
predicted that the effects were due to phosphorylation of
the enzymes by an endogenous protein kinase that con-
taminated their preparations. It was subsequently shown
that this protein kinase was itself activated by phos-
phorylation by an upstream kinase [10]. In 1987, Carling
et al. [11] made the discovery that the inactivation of
ACCandHMG-CoAreductasewerebothcatalysedbya
single protein kinase. As it became clear that it was a true
multi-substrate kinase, they renamed it AMP-activated
protein kinase after its allosteric activator 5 -AMP [12].
Hardie [13] has described AMPK as a ‘fuel gauge’ and
‘guardian of energy status’, implying the fundamental
role of AMPK in energy metabolism and maintaining
body energy balance. AMPK is a heterotrimeric enzyme
complex which consists of α, β and γ subunits, each of
which has two or more isoforms that are encoded by
distinct genes and are differentially expressed in various
tissues. The α subunit contains the catalytic domain,
including the important regulatory Thr172 residue, which
isphosphorylatedbyupstreamkinases.Theβ subunithas
glycogen-binding C-terminal domains that are sufﬁcient
ontheirowntoformacomplexwiththeα andγ subunits.
High cellular glycogen content exerts an inhibitory effect
on AMPK through an interaction with the β subunit
in skeletal muscle, although the exact mechanism is un-
known[14].Theγ subunitofAMPKwasﬁrstrecognized
by Bateman [15] and contains four repeats forming two
domains. Each of these domains binds one molecule of
AMP or ATP ion in a mutually exclusive manner [16],
consistent with the ﬁndings that high concentrations of
ATP antagonize activation of AMPK by AMP.
For many years, the upstream kinase(s) that phos-
phorylates Thr172 on the α subunit of AMPK remained
unidentiﬁed. In recent years, it has been established
that the major upstream kinase in mammalian cells is a
complex of the protein kinase LKB1 and two accessory
subunits STRAD (Ste20-related adaptor) and MO25
(mouseprotein25)[17–19].LKB1alsoactsasanupstream
kinase of at least 12 other AMPK-related kinases [20,21].
It has also been found to be a tumour suppressor and was
identiﬁed in humans as a gene carrying an autosomal-
dominant mutation in Peutz–Jeghers syndrome [19,22].
The STRAD subunit is essential for the ability of the
LKB1 complex to phosphorylate Thr172 on AMPK [18].
Besides LKB1, STRAD and MO25, AMPK can also be
activated by an LKB1-independent mechanism involving
CaMKs (Ca2+/calmodulin-dependent protein kinases).
AMPK exerts its metabolic effects through its inter-
actions with various metabolic pathways. Activation of
these metabolic pathways via AMPK activation leads
to remodelling of various components of the metabolic
syndrome [23] (Figure 1). AMPK plays a major role in
providing ATP in the midst of energy depletion via its
interactions with various metabolic pathways (Figure 2).
Furthermore, AMPK also has direct and indirect effects
on the cardiovascular system, and the understanding of
such effects provides the rationale of targeting AMPK
as a new therapeutic modality for the treatment and
prevention of CVD.
AMPK: DIRECT EFFECTS ON THE
CARDIOVASCULAR SYSTEM
Congestive cardiac failure, LV (left ventricular) hyper-
trophy, myocardial ischaemia and diabetic cardiomyo-
pathy are all associated with disturbances of cardiac
energyhomoeostasis.Inthesepathologicalstates,AMPK
activity is up-regulated in response to an increased
AMP/ATP ratio (energy-depleted state). AMPK
switches on energy-generating pathways to increase
cardiac myocyte fatty acid uptake [24] and increase glu-
cose uptake by increasing the translocation of GLUT-4
(glucose transporter-4) in a PI3K (phosphoinositide
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Figure 1 Physiological and pharmacological activation of AMPK results in remodelling of various components of the
metabolic syndrome
3-kinase)-independent manner [5], while also enhancing
glycolysis via PFK-2 (phosphofructokinase-2) activation
[25]. At the same time, AMPK turns off protein synthesis
pathways by activating eEF2 (eukaryotic elongation
factor 2) kinase, resulting in the phosphorylation and
inactivation of eEF2 and by decreasing Thr389 phos-
phorylation of p70RSK (p70 ribosomal protein S6 kinase),
another important kinase which is involved in protein
synthesis [26] via mTOR (mammalian target of rapa-
mycin) inhibition [26,27] (see Figure 2).
AMPK and cardiac ischaemia
During cardiac ischaemia, the AMP/ATP ratio is
increased as a result of decreased oxidative metabolism
of both NEFAs [non-esteriﬁed fatty acids (‘free fatty
acids’)] and glucose due to diminished oxygen supply
in the face of increased glycolytic ATP production and
glucose transport [28]. Russell et al. [5] have shown that
AMPK activation using AICAR (5-amino-4-imidazole-
carboxamide riboside-1-β-d-ribofuranoside) in an
invitroratmodelincreasedtranslocationofglucosetrans-
porters(i.e.GLUT-4)intothesarcolemmaand,hence,in-
creased glucose uptake. Furthermore, AMPK also phos-
phorylatesandactivatesPFK-2,leadingtotheproduction
of fructose 2,6-bisphosphate, a potent stimulator of gly-
colysis.AMPKmaybenecessaryforadiponectintoexert
its cardioprotective effect against ischaemia/perfusion
injury [29]. Both the α1 and α2 subunits of AMPK
are activated during myocardial ischaemia, with the
α2 subunit being activated to a greater extent [30,31].
Previous studies in transgenic mice have shown that
decreased α2 activity resulted in reduced cardiac glucose
uptake following ischaemia [32] and impaired recovery
of LV systolic function [31]. Additionally, in transgenic
mice expressing a kinase-dead form of the enzyme,
phosphocreatinine was also lower after reperfusion [31].
These observations suggest that activation of AMPK fol-
lowing ischaemia has a cardioprotective effect and results
in lesser cardiac injury and faster recovery. Calvert et al.
[33] have also shown that activation of AMPK with MF
(metformin) resulted in decreased myocardial injury in
both diabetic and non-diabetic mice. This may be a result
of deriving ATP from more energy-efﬁcient glucose
metabolismfromincreasedAMPK-mediatedglucoseup-
take and glycolytic ﬂux in the face of oxygen deprivation
[34,35].
However, ischaemic-induced activation of AMPK
may be detrimental to the ischaemic heart, as suggested
by Dyck and Lopaschuk [36]. During ischaemia, circul-
ating fatty acid levels are elevated [37], which may be
detrimental to the ischaemic heart [38,39]. Activation of
AMPK leads to increased fatty acid uptake and inhib-
ition of malonyl-CoA, a potent endogenous inhibitor
of mitochondrial fatty acid uptake. This results in
accelerated mitochondrial fatty acid uptake and, hence,
increased mitochondrial acetyl-CoA production from
β-oxidation. High levels of acetyl-CoA have an
inhibitory effect on PDH (pyruvate dehydrogenase),
reducing the amount of pyruvate being converted into
acetyl-CoA and, hence, reduced glucose oxidation (the
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Figure 2 AMPK activation leads to activation of different metabolic pathways
AMPK plays an important role in whole-body energy homoeostasis as it regulates and interacts with different key metabolic pathways. Activation of AMPK, secondary
to a change in the AMP/ATP ratio or activation by upstream kinases, such as CAMKK (CaMK kinase) and LKB1 leads to a switching on of energy-production pathways,
such as glucose and lipid metabolism, and a turning off of energy-metabolic processes, such as protein synthesis, which is not required for immediate cell survival.
(i) Fatty acid metabolism. AMPK activation leads to increased translocation of CD36, a fatty-acid-transport protein, which increases fatty acid (FA) ﬂux into cells and
subsequent uptake into mitochondria for β-oxidation. CPT-1 inhibits fatty acid inﬂux and acts as a gatekeeper for the mitochondrial uptake of fatty acids. Activation
of AMPK leads to the inhibition of ACC2, which normally converts acetyl-CoA into malonyl-CoA. The inhibitory effect of malonyl-CoA on CPT-1 is hence removed,
leading to unopposed intake of fatty acids into mitochondria. Furthermore, phosphorylating and inactivation of ACC1 by AMPK activation reduces fatty acid synthesis
and turns off the expression of lipogenic genes, such as fatty acid synthase. MCD, malonyl-CoA decarboxylase. (ii) Glucose metabolism. Activation of AMPK increases
translocation and retention of GLUT-4 in the plasma membrane, as well as increased transcription of the GLUT-4 gene, leading to increased glucose uptake. It also
enhances glycolysis via activation and phosphorylation of PFK-2. (iii) Protein metabolism. p70RSK (p70S6K) is a one of the key kinases involved in protein synthesis.
mTOR activates p70RSK and leads to increased protein synthesis. When AMPK is activated, the activation of p70RSK is blocked as a result of the inhibition of mTOR.
Activation of AMPK also results in phosphorylation and inactivation of eEF2, and subsequent inhibition of protein synthesis. eEF2K, eEF2 kinase.
exact mechanisms remain undeﬁned). The proposed
mechanisms for these detrimental effects of high
circulating fatty acids include: (i) accumulation of toxic
intermediates of fatty acid oxidation, such as long-chain
acyl-CoA thioesters and long-chain acylcarnitines [38],
(ii) inhibition of glucose oxidation via inhibition of the
PDH complex by fatty-acid-derived acetyl-CoA, and
(iii) accumulation of glycolytic by-products such as
protons and lactate. These valuable observations have
afﬁrmed the role of AMPK in cardiac ischaemia and
suggested a potential role for therapeutic targeting in the
treatment of myocardial ischaemia and MI (myocardial
infarction).
AMPK and cardiac arrhythmias
Mutations of the γ 2 subunit of AMPK have also been
shown to contribute to glycogen storage disease and
Wolff–Parkinson–White syndrome [40]. Gollob et al.
[40] identiﬁed in 2001 a mutation (Arg531Gly) in the
AMPK γ 2 subunit (PRKAG2 gene) to be responsible
for Wolff–Parkinson–White Syndrome and early onset
of atrial ﬁbrillation and conduction disease. Using a
transgenic model targeting the murine gene, Davies et al.
[41] demonstrated striking cardiac manifestations, such
as hypertrophy, impaired contractile function, electrical
conduction abnormalities and marked glycogen accumu-
lation. Furthermore, Sidhu et al. [42] have identiﬁed a
C   The Authors Journal compilation C   2009 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.AMPK pathway as a potential therapeutic target in cardiometabolic disease 611
distinct atrial ventricular accessory pathway and a pro-
longed QRS in this transgenic mice model. However, the
effectsofthemutationsdescribedinthisgeneontheover-
all activity of AMPK varies in the different experimental
models [43,44]. It is still uncertain whether these cardiac
manifestationsaretheresultofdisease-causingmutations
or secondary to glycogen deposition. Murphy et al. [45]
postulated that the manifestations of AMPK disease may
be due to defects in energy utilization or in speciﬁc cellu-
lar substrates, rather than mere passive deposition of gly-
cogen.Nonetheless,theseﬁndingsillustrateanimportant
role for AMPK in cardiac hypertrophy and arrhythmias.
AMPK and cardiac hypertrophy, cell
growth and gene transcription
AMPK may play a further role in the regulation of
normal cardiac cell growth [31,32] and energy regulation
in the hypertrophied heart [46], via its effects on
protein synthesis [47,48]. Mutations in γ 2 subunits not
only cause glycogen overload in the heart and Wolff–
Parkinson–White syndrome, but also hypertrophy and
HF (heart failure) [40,49–51]. The severity of the defect
also correlates with the severity of the disease. eEF2 is
the main mediator of the translocation step in protein
synthesis and is inhibited through phosphorylation of
eEF2 kinase. p70RSK regulates protein synthesis through
the same pathway or via phosphorylation of ribosomal
protein S6. Chan et al. [48] have shown that AMPK
not only regulates eEF2 kinase, but also exerts effects
on protein synthesis via the mTOR pathway, ultimately
leading to inhibition of p70RSK. Furthermore, Chan et al.
[48] have shown that activation of AMPK using MF and
AICAR results in inhibition of protein synthesis, and is
associated with prevention and regression of cardiac
hypertrophy. However, studies in transgenic mice have
shown that elevated AMPK activity is associated with
the accumulation of large amounts of glycogen, leading
to dramatic LV hypertrophy and arrhythmias [46,52]. It
remains uncertain, therefore, whether AMPK activation
in the hypertrophied heart is beneﬁcial [48,53] or
deleterious, and further studies are required.
AMPK and vascular and endothelial
function
AMPK also plays an important role in the regulation
of vascular function and structure. It activates eNOS
(endothelial NO synthase) in endothelial cells and
cardiac myocytes by phosphorylation at Ser1177 (human
sequence)[54,55].eNOSactivationleadstoaugmentation
of vascular tone, platelet aggregation, leucocyte adher-
ence and vascular smooth muscle proliferation [56].
Using a diabetic rat model, Suzuki et al. [57] have
shown that activation of AMPK using a cAMP phos-
phodiesterase inhibitor, cilostazol, restores endothelial
function independently of cAMP. Administration of
cilostazol leads to phosphorylation of AMPK and
subsequent phosphorylation of eNOS and increased NO
production. Other AMPK activators, AICAR [58], MF
[59] and rosiglitazone [60], have all been shown to
increase NO production in human aortic endothelial
cells via the AMPK pathway. Additionally, AMPK also
appears to have a role in angiogenesis, promoting the ac-
tion of the HIF-1α (hypoxia-inducible factor-1α)/VEGF
(vascularendothelialgrowthfactor)pathway[61,62],and
inhibitingAngII(angiotensinII)-inducedsmoothmuscle
cell proliferation [63]. Furthermore, activation of AMPK
using AICAR has been shown to inhibit palmitate-
induced endothelial cell apoptosis through suppression
of ROS (reactive oxygen species) [64]. It is clear that
AMPK plays a central role in vascular biology.
AMPK: INDIRECT EFFECTS ON THE
CARDIOVASCULAR SYSTEM
Recent ﬁndings have shown that levels of adipocytokines
such as adiponectin and leptin correlate with the dev-
elopment of different components of the metabolic
syndrome [65]. AMPK has been suggested to play a role
in mediating the metabolic and vascular effects of the
key adipocytokines [66,67].
AMPK and leptin
Leptin is an adipocyte-secreted hormone that plays a
pivotal role in the regulation of food intake, energy
expenditure, body weight and neuroendocrine function
[68]. Leptin stimulates fatty acid oxidation [69] and
glucose uptake [70], and prevents lipid accumulation
outwith adipose tissue, preventing lipotoxicity [71]. De-
position of ectopic fat in pancreatic β-cells, myocardium
and skeletal muscle contributes to the pathogenesis of
Type 2 diabetes mellitus, cardiomyopathy and insulin
resistancerespectively.Leptinisknowntoexertitseffects
via the AMPK pathway, stimulating phosphorylation
and activation of the α2 catalytic subunit of AMPK
selectively in skeletal muscle [69]. Leptin also suppresses
ACC2 activity, thereby stimulating fatty acid oxidation
in muscle. AMPK also inhibits lipogenesis and ectopic
fat deposition in the liver [72]. AMPK is also a key
regulator of leptin action in the hypothalamus and
a ‘master regulator’ of food intake. Minokoshi et al.
[73] have shown that inhibition of AMPK activity by
leptin speciﬁcally in the arcuate and paraventricular
nuclei is essential for its anorexigenic and weight-loss
effects.
AMPK and adiponectin
Adiponectin, an adipose-speciﬁc protein present in high
concentrations in the circulation, was ﬁrst identiﬁed in
1996. It possesses anti-atherogenic, insulin-sensitizing
and anti-inﬂammatory properties. Yamauchi et al. [66]
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Table 1 Different AMPK ‘activators’ and their limitations in clinical use
For further details of AICAR and MF studies, see Tables 2 and 3 respectively. PKC, protein kinase C.
AMPK activator Possible mechanism(s) of AMPK activation Activation of other pathways Limitation(s)
AICAR (i) Direct activation followed by allosteric
modiﬁcation
(i) Stimulates adiponectin release; (ii) inhibits
cytokines such as TNF-α and IL-6
(i) Short half-life; (ii) variable effectiveness;
(iii) only intravenous forms available; (iv)
may cause bradycardia and signiﬁcant
hypoglycaemia
MF (i) Indirect activation; (ii) via alteration of
the AMP/ATP ratio as a result of
inhibition of Complex I in the respiratory
chain; (iii) other unknown mechanisms
(i) Anticancer effects via its effects on p53;
(ii) up-regulates eNOS and increases NO
bioactivity; (iii) enhances fatty acid
oxidation, which leads to alleviation of
endothelial lipotoxicity
(i) Indirect AMPK activation; (ii) doses and
duration of MF required for AMPK
activation are not determined; (iii) higher
doses of MF result in intolerable
gastrointestinal side effects
TZDs (i) Indirect activation; (ii) via alteration of
the AMP/ATP ratio, possibly similar to
MF; (iii) via adiponectin
(i) Anti-atherosclerotic and anti-inﬂammatory
effects via adiponectin; (ii) effects on
mitochondrial biogenesis; (iii) exerts
antioxidative effects by inhibiting PKC via
AMPK activation
(i) Indirect inhibition; (ii) risk of developing
ﬂuid retention; (iii) risk of developing
cardiovascular events is yet to be
determined
Statins (i) Indirect activation; (ii) does not alter the
AMP/ATP ratio; (iii) other unknown
mechanisms
(i) HMG-CoA reductase inhibition; (ii)
activation of AMPK/eNOS/ACC
(i) Doses required for AMPK activation in
humans are still to be determined
Compound A-769662 (i) Direct activation (i) Increased fatty acid oxidation; (ii)
decreased plasma and liver triacylglycerol
levels; (iii) inhibits fatty acid synthesis
(i) Poor oral bioavailability; (ii) data on
long-term AMPK activation are awaited
have shown that adiponectin stimulates glucose utiliz-
ation and fatty acid oxidation via the AMPK pathway.
Furthermore, adiponectin has been shown to reduce
infarct size, improve LV function and remodelling, and
increase coronary ﬂow during reperfusion in animal
models. The underlying mechanisms are thought to be
phosphorylation of eNOS, AMPK Thr172 and Akt Ser473
[74].Adiponectin-deﬁcientmicehavebeenshowntohave
progressive cardiac remodelling in a pressure-overloaded
condition due to reduced AMPK signalling and
worsening insulin resistance [75]. Therefore the AMPK
pathwayisnotonlycriticalforthemetabolicandinsulin-
sensitizing actions of adiponectin, but also its cardiopro-
tective effects in myocardial ischaemia and reperfusion.
AMPK ACTIVATORS: PHARMACOLOGICAL
TOOLS AND THERAPEUTIC POTENTIAL
As we have seen above, AMPK is a pivotal enzyme that
regulates diverse signals in metabolic pathways and has
direct and indirect effects on the heart and vasculature.
AMPK activation has not only been shown to alleviate
various components of the metabolic syndrome, but
may also improve LV hypertrophy and reduce cardiac
injury in ischaemia. AMPK is also a key mediator of
the anti-atherosclerotic and insulin-sensitizing effects
of adiponectin. Therefore it is clearly an attractive
therapeutic target in cardiometabolic disease. A number
of AMPK activators are available as pharmacological
tools and some are in clinical use (Table 1).
AICAR
AICAR is an adenosine analogue which activates
AMPK through direct binding, followed by allosteric
modiﬁcation. It is initially taken up by adenosine
transporters and subsequently phosphorylated to ZMP
(5-aminoimidazole-4-carboxamide-1-β-d-furanosyl 5 -
monophosphate) within the cell, which mimics
AMP in AMPK signalling [76]. AICAR was ﬁrst
developed to block adenosine reuptake in the ischaemic
heart, promoting stimulation of adenosine membrane
receptors. In 1997, treatment with acadesine (AICAR)
before and during surgery was shown to reduce early
cardiac death, MI and combined adverse cardiovascular
outcomes [77], although the mode of action via AMPK
was not fully appreciated at that time.
AICAR is now widely used in the laboratory
setting, particularly in experiments relating to glucose
metabolism, insulin signalling pathways and lipid meta-
bolism. In recent years, AICAR has been shown to
reverse various aspects of the metabolic syndrome in
animal models [23,78–80] and healthy human subjects
[81] (Table 2). AICAR has also been shown to stimulate
adiponectin and inhibit cytokines, such as TNF-α
(tumour necrosis factor-α) and IL-6 (interleukin-6),
which have been implicated in the development of
obesity-induced insulin resistance [82–85]. Unfortun-
ately, AICAR is far from an ideal activator of the
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Table 2 Various studies of AMPK activation using AICAR and their major ﬁndings
HDL, high-density lipoprotein; IR, insulin-resistant; OGTT, oral glucose tolerance test; SBP, systolic blood pressure.
Study Type of subjects Dosage Duration Major ﬁnding(s)
Iglesias et al. [80] IR high-fat-fed rats Subcutaneous injection of 250 mg/kg
of body weight
24 h (i) Enhanced whole-body, muscle and liver insulin
action; (ii) reduced hepatic glucose output
Buhl et al. [23] Obese Zucker rats exhibiting IR,
hyperlipidaemia and
hypertension
Subcutaneous injection of 0.5 mg/g of
body weight
7 weeks (i) Decreased plasma triacylglycerol and NEFAs, and
increased HDL; (ii) lower SBP; (iii) normalized
OGTT and decreased fasting glucose and insulin;
(iv) tendency towards decreased intra-abdominal
fat content
Bergeron et al. [79] Obese Zucker rats Bolus at 100 mg/kg of body weight
and constant infusion at 10 mg·
kg−1 of body weight·min−1
60 min (i) Increased glucose transport in red gastrocnemius
muscle, whereas insulin had no effects; (ii)
suppression of endogenous glucose production and
lipolysis
Song et al. [78] ob/ob mice Subcutaneous at 1 mg/g of body
weight
7 days (i) Corrected hyperglycaemia, improved glucose
tolerance, and increased GLUT-4 and hexokinase II
protein expression in skeletal muscle
Cuthbertson et al. [81] Healthy men Intravenous infusion at 10 mg·kg−1
of body weight·h−1
9 h (i) Increased human skeletal muscle 2-deoxyglucose
uptake and whole-body glucose disposal
AMPK pathway in the clinical settings because of its
short half-life, requirement for intravenous infusion and
variable effectiveness. It also causes bradycardia and can
lead to hypoglycaemia when administered intravenously.
Therefore there is great interest in developing a more
potent, safer and more speciﬁc activator.
Metformin
MF has been usedtotreat diabetes formorethan50 years
and is associated in observational studies with reduced
mortality and improved outcomes in patients with CHF
(chronic HF) [86,87]. It is the preferred antidiabetic med-
ication for obese patients with Type 2 diabetes mellitus
becauseofitspropertytostabilizeweightandreducecar-
diovascular events when used as monotherapy [88]. Re-
centclinicalstudieshaveshownthattheeffectsofMFmay
gobeyondimprovingHbA1c (glycatedhaemoglobin)and
may include reductions in cardiovascular end points in
Type 2 diabetes mellitus and HF. This wide spectrum of
cardiovascular-protective effects may be attributable to
its activation of AMPK and its downstream pathways.
MF has been shown to activate AMPK in myocytes
[89–91], hepatocytes [92] and skeletal muscle cells [92].
MF decreases hepatic glucose production and increases
skeletalmuscleglucosedisposal.TherapeuticdosesofMF
have been shown to increase AMPK α2 subunit activity
in human skeletal muscle with an associated increase in
phosphorylation of AMPK on Thr172 and decreased
ACC2 activity [93]. MF can also up-regulate eNOS
and increases NO bioactivity via AMPK activation [94].
Furthermore, AMPK activation by MF enhances fatty
acid oxidation, which leads to alleviation of endothelial
lipotoxicity and improved endothelial function [95].
Moreover, MF has also been shown to have anticancer
effects in a recent study via its indirect AMPK activation
[96]. However, the precise mechanisms of how MF
activates AMPK are still poorly understood.
Even though MF is regarded as an AMPK activator, it
has not been shown to bind directly to AMPK; neither
does it regulates its own phosphorylation and dephos-
phorylation in cell-free assays [97]. One hypothesis
is that it activates AMPK by inhibiting Complex I of
the respiratory chain, which subsequently causes an
increase intheAMP/ATP ratio[98,99].Infact, inhibition
of the respiratory chain in the intestinal mucosa may
account for the gastrointestinal side effects of the drug,
and this property may account for the propensity of
its predecessor biguanides phenformin to cause lactic
acidosis. MF is transported into intestinal cells mainly by
OCT-1 (organic cation transporter-1), but phenformin
penetrates cell membranes without active transport.
Identiﬁcationofpolymorphismsingenesencodingcation
transporterproteinsmayultimatelyexplaindifferencesin
tolerance and response to MF [100]. Interestingly, there
are also studies suggesting that AMPK can be activated
by MF without changes in the AMP/ATP ratio [97,101],
and MF can also exert its beneﬁcial metabolic effects
on cardiac myocytes in an AMPK-independent manner
[102].
However, we should be mindful that extra caution is
required if we are to use these results to extrapolate to the
effects of MF on AMPK. First, variable doses of MF have
been used in these studies. The plasma MF concentration
in clinical use is usually approx. 10 μmol/l [103], whereas
the doses used in in vivo and in vitro experiments are
consistentlyhigher,intherangeof1–10mmol/l(Table3).
Saeedi et al. [102] have shown that lower doses of MF
(i.e. 2 mmol/l) failed to activate AMPK and caused no
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Table 3 Studies of AMPK activation using MF and their major ﬁndings
IRI, ischaemia/reperfusion injury; MAPK, mitogen-activated protein kinase; PKC, protein kinase C.
Study Aim(s) Subjects Dosage Key ﬁnding(s) Clinical application
Calvert et al. [33] To examine the
cardioprotective effects
of MF
Murine models 125 μg/kg of body
weight compared with
saline (286-fold lower
than maximum
antihyperglycaemic
dose)
(i) Reduction in myocardial
injury in both diabetic
and non-diabetic mice;
(ii) increased AMPK
activity and eNOS
phosphorylation
Cardioprotective effects of
MF might be secondary
to eNOS activation via
AMPK pathway
Solskov et al. [134] To determine the effects of
a single dose of MF on
cardiac protection
against IRI
Wistar rats Single dose of MF
(250 mg/kg of body
weight) compared with
saline
(i) Reduction in MI size; (ii)
2-fold increase in AMPK
α1 subunit activity
MF might reduce MI size
in pre-treated subjects
via AMPK activation
Saeedi et al. [102] To determine whether MF
has effects on the
metabolism of heart
muscle, independent of
the AMPK pathway
Sprague–Dawley rats 2 mmol/l (this dose has
greatest cellular
metabolic effects
without an impact on
cellular energy status)
(i) Increased rate of
glycolysis, glucose uptake
and fatty acid oxidation;
(ii) AMPK was not
activated by 2 mmol/l MF
MF has AMPK-independent
metabolic effects,
possibly via PKC and
p38 MAPK pathways
Kovacic et al. [91] To determine whether Akt
activation induced by
insulin negatively
regulates AMPK
activities
Akt transgenic mice and
adenovirus-infected
neonatal rat cardiac
myocytes with
mutant forms of
Akt1 and Akt2
5 mmol/l MF (i) Insulin increased Akt
phosphorylation and
reduced AMPK
phosphorylation;
(ii) administration of MF
overcame Akt-dependent
AMPK suppression;
(iii) suggests a cross-talk
between Akt and AMPK
pathway
AMPK can be activated by
MF via insulin-
independent pathways,
but higher doses of MF
are required
Zhang et al. [89] To examine whether MF
activates AMPK in the
heart via increasing
cytosolic AMP
Sprague–Dawley rats 10 mmol/l MF (i) MF increases AMPK
activity preceded by and
correlated with increased
cytosolic AMP, but the
overall AMP/ATP ratio
remained unchanged
MF activates AMPK without
altering the total
AMP/ATP ratio; a high
dosage of MF is
required for AMPK
activation.
changes in energetic state. On the contrary, Hawley et al.
[97] have shown that lower doses of MF can actually
produce AMPK activation without a signiﬁcant change
in the cellular AMP/ATP ratio. Other research groups
have reported that AMPK activation required higher
doses of MF (i.e. 5–10 mmol/l) [89,91] (Table 3) and
suggested that higher doses of MF are required to cause
changes in the energetic state and, hence, subsequent
AMPK activation. However, these divergent results
may be the result of different exposure time of MF. For
instance, Yang and Holman [90] have shown that a lower
dose of MF (1 mmol/l) activated AMPK and increased
cardiac myocyte glucose uptake after a prolonged
exposure of 18 h. On the other hand, Bertrand et al. [104]
have shown that short exposure (4 h) of MF can result in
AMPK activation if much higher doses of MF were used
(5–10 mmol/l). Therefore AMPK can be activated by MF
in a time- and concentration-dependent manner. Clearly
further studies are required to determine the time and
concentration of MF which will result in the maximal
beneﬁcialeffectsofAMPKactivationwithoutintolerable
side effects.
TZDs (thiazolinediones)
TZDs (i.e. rosiglitazone and pioglitazone) are ligands for
the nuclear hormone receptor family member PPAR-γ
(peroxisome-proliferator-activated receptor-γ) [105].
Both rosiglitazone and pioglitazone have been shown
to activate AMPK in intact cells [106,107]. TZDs can
alsoactivateAMPKbystimulatingthereleaseandexpres-
sion of circulating adiponectin from adipose tissue
[66,67] or indirectly by increasing the cellular AMP/ATP
ratio, possibly by a similar mechanism to biguanides
[108]. Both rosiglitazone and pioglitazone have been
suggested to have additional and protective beneﬁcial
anti-atherosclerotic and anti-inﬂammatory effects [109].
Furthermore,TZDshavealsobeenshowntohavediverse
beneﬁcial effects on endothelial function, TNF-α,N O
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and endothelial cell proliferation via AMPK-dependent
and PPAR-γ-independent mechanisms [110–114]. These
effects may translate into an improvement in clinical
outcomes in patients with cardiometabolic disease. Prev-
ious studies have raised the intriguing possibilities that
these effects may be mediated via AMPK activation
[107,115,116]. However, as with MF, we are not certain
whether AMPK activation is the key to these beneﬁcial
clinical effects on cardiovascular system. Furthermore,
we also need to be very cautious when we try to translate
theseobservationsinanimalstudiestotheclinicalsetting.
The doses and type of TZDs that have been shown to
activate AMPK vary among different research groups
and the doses used in these animal studies may not be
applicable to human subjects. Furthermore, the majority
of these in vivo studies are short-term studies examining
the effects of acute AMPK activation and its metabolic
effects; however, the effects of long-term AMP activation
by TZDs have yet to be determined. Nonetheless, the
cardiovascular-protective effects of TZDs are evidenced
in the recently published post-hoc analysis from the
PROactive (PROspective pioglitAzone Clinical Trial In
macroVascular Events) study [116]. This showed that
patients who have chronic kidney disease and received
pioglitazone are less likely to reach composite end points
of all-cause death, MI and stroke, independent of the
severity of renal impairment.
However,itshouldbenotedthatTZDuseisassociated
with the risk of ﬂuid retention which may exacerbate
HF [117]. In a recent meta-analysis, Lago et al. [118]
reported that TZDs increased the risk of developing
CHF, probably as a result of ﬂuid retention, across
a wide background of cardiac risk [relative risk, 1.72
(95% conﬁdence interval, 1.21–2.42); P=0.002]. There
is also a concern that these agents may be associated
with additional cardiovascular (MI and stroke) risk in
patients with Type 2 diabetes mellitus with rosiglitazone.
However, it should be noted that these meta-analyses
included many small trials [119], whereas large clinical
trial data have shown no sign of these cardiovascular
events [RECORD (Rosiglitazone Evaluated for Cardiac
Outcomes and Regulation of glycemia in Diabetes) and
PROactive] [117,120]. The EMEA (European Medicines
Evaluation Agency) for Medicinal Products for Human
Use has adopted a scientiﬁc opinion in January 2008
recommendingtheinclusionofanewwarningstatingthat
the use of rosiglitazone in patients with ischaemic heart
disease and/or peripheral arterial disease is not recom-
mended. A recent FDA (Federal Drug Administration)
review suggested that more large randomized studies
with active comparators should be conducted by the
manufacturers.
Statins
Statins are widely prescribed in patients with the meta-
bolicsyndromeowingtothehighincidenceofhypercho-
lesterolaemia in this group of patients. There is mounting
evidence to suggest that the clinical beneﬁts of statins are
beyond its lipid-lowering effects. The clinical efﬁcacy of
statin treatment in reducing cardiovascular mortality and
morbidity in patients without and with diabetes are well-
proveninclinicaltrials,suchastheHPS(HeartProtection
Study) and the CARDS (Collaborative Atorvastatin Dia-
betes Study) [121–124]. Besides its cholesterol-lowering
effect via HMG-CoA reductase inhibition, statins have
also been shown to activate AMPK in human and bovine
endothelial cells [125]. Xenos et al. [126] have shown
that AMPK protein levels in human endothelial cells are
increased after being treated with ﬂuvastatin for 2 days.
Sun et al. [125] have also shown that atorvastatin and
lovastatincausearapidactivationofAMPK/eNOS/ACC
in mouse myocardium and endothelial cells. The
atorvastatin dose used in that study was 50 mg/kg of
body weight in mice which is equivalent to 80 mg/day
in human. That study has shown that atorvastatin did not
alter the cellular AMP/ATP ratio, suggesting a different
mechanism of AMPK activation. The beneﬁcial effects of
statins on endothelial function have been suggested to be
theresultofitsabilitytoup-regulateeNOS[121,122,127–
129] and its anti-inﬂammatory and anti-artherogenic
effects [124,130]. These observations have all suggested
that AMPK activation might be the key to the pleio-
tropic effects of statins on cardiovascular protection;
however,furthermechanisticandtranslationalstudiesare
required to show that AMPK activation is indeed the
key to the effects of statin treatment, as well as examin-
ing the doses of different statins required to activate
AMPK.
Compound A-769662
Cool et al. [131] have identiﬁed a thienopyridone
family of AMPK activators, compound A-769662,
which stimulates AMPK directly in partially puriﬁed
rat liver and inhibits fatty acid synthesis in primary
rat hepatocytes. Short-term treatment of normal
Sprague–Dawley rats with A-769662 decreases liver
malonyl-CoA levels and the respiratory exchange ratio,
˙ V CO2/ ˙ V O2 (carbon dioxide production/oxygen consump-
tion), indicating an increased rate of whole-body fatty
acid oxidation. In ob/ob mice, treatment with compound
A-769662 has been shown to decrease plasma glucose,
reduce weight gain and signiﬁcantly decrease both
plasma and liver triacylglycerol (triglyceride) levels.
These results demonstrate that small-molecule-mediated
activation of AMPK in vivo is feasible and, therefore,
represents a promising approach for the treatment of
Type 2 diabetes mellitus and the metabolic syndrome.
However, the compound has poor oral bioavailability,
limiting its use in clinical settings.
An alternative small-molecule compound that is
safe, potent, acts directly on AMPK and has good oral
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bioavailability would be an attractive candidate to pro-
gress towards clinical development.
CONCLUSIONS
Activation of the AMPK pathway may be the key in
treating and preventing various cardiometabolic diseases;
however, it is still uncertain whether direct activation of
the AMPK pathway in the absence of a physiological
stresswillbebeneﬁcialordeleteriousoverallinhumans.It
is hoped that chronic activation of AMPK will not result
in ‘over-compensatory’ activation of other systems such
as the RAAS (renin–angiotensin–aldosterone system)
activation in HF. Alterations in cardiac AMPK activity
are associated with a number of cardiovascular-related
diseases, such as pathological cardiac hypertrophy [50],
myocardial ischaemia [36], glycogen storage cardio-
myopathy [52] and Wolff–Parkinson–White syndrome
[51], suggesting a possible maladaptive role in such con-
ditions.Anderssonetal.[132]describedantisatietyeffects
of AMPK, which may lead to weight gain. Furthermore,
McCullough et al. [133] also demonstrated that activated
AMPK may be harmful in stroke. All of these uncer-
tainties will need to be clariﬁed by further translational
studies,andmucheffortisstillrequiredtodeﬁnetheroles
of AMPK activation in various conditions that have been
discussed above. Furthermore, it is also a great challenge
for pharmaceutical companies to produce a speciﬁc
AMPK activator that has predictable effects owing to
its heterotrimeric structure and its complex interactions
with various upstream and downstream kinases. The
other approach in which many researchers have adopted
is to develop a compound that targets the downstream
kinases of AMPK [i.e. a malonyl-CoA activator or
CPT-1 (carnitine palmitoyltransferase-1) activator]. The
AMPK/malonyl-CoA/CPT-1 axis might represent an
interesting pathway for further research in cardiac
substrate utilization and fatty acid metabolism. The
AMPK–adipocytokine interaction has also formed
the rationale for the development of new treatment
modalities for the treatment of obesity. Lastly, AMPK/
mTOR/eEF2/p70RSK axis modulation may be the key
to understanding the pathogenesis of cardiac myocyte
hypertrophy and mitochondrial biogenesis. A greater
understanding of the biochemistry and physiology of
AMPK and a better understanding of the mechanisms
of action of existing agents have nonetheless opened up a
new horizon for the treatment and prevention of cardio-
vascular and metabolic disease.
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